Taliansko - taliančina - Ministero della Salute

bayer ag - flupyradifurone; - concentrato solubile - 200.0 g/l i valori indicati sono per 100 g di prodotto. - flupyradifurone; 17,1%; (200; g/l) - insetticida

Taliansko - taliančina - Ministero della Salute

bayer ag - fosetyl-aluminium; - granuli autodispersibili - 80.0 g i valori indicati sono per 100 g di prodotto. - fosetil; alluminio; 80% - fungicida

Taliansko - taliančina - Ministero della Salute

bayer ag - spiroxamina; - sospensione di capsule - 30.6 g i valori indicati sono per 100 g di prodotto. - spiroxamina; 30,6%; (300; g/l) - fungicida

Taliansko - taliančina - Ministero della Salute

bayer ag - fluopyram; tebuconazolo; - sospensione concentrata - 17.7 g; 17.7 g i valori indicati sono per 100 g di prodotto. - fluopyram; 17,7%; (200; g/l); tebuconazolo; 17,7%; (200; g/l) - fungicida

Európska únia - taliančina - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasie colorettali - antineoplastic agents, protein kinase inhibitors - stivarga è indicato come monoterapia per il trattamento di pazienti adulti con:metastatico del colon-retto (crc) che sono stati trattati in precedenza o che non sono considerati candidati per, terapie disponibili - questi includono fluoropyrimidine a base di chemioterapia, la terapia anti-vegf e di una terapia anti-egfr;non resecabile o metastatico, i tumori stromali gastrointestinali (gist) che ha attuato o che sono intolleranti ad un precedente trattamento con imatinib e sunitinib;carcinoma epatocellulare (hcc) che sono stati precedentemente trattati con sorafenib.

Taliansko - taliančina - Ministero della Salute

bayer ag - etefon; - concentrato solubile - 39.6 g i valori indicati sono per 100 g di prodotto. - etefon; 39,6%; (480; g/l) - fitoregolatore - fitoregolatore - (xn) nocivo

Taliansko - taliančina - Ministero della Salute

bayer ag - fenhexamid; - sospensione concentrata - 42.74 g i valori indicati sono per 100 g di prodotto. - fenhexamid; 42,8%; (500; g/l) - fungicida

Taliansko - taliančina - Ministero della Salute

bayer ag - paecilomyces lilacinus ceppo 251; - concentrato dispersibile - 20.0 g i valori indicati sono per 100 g di prodotto. - paecilomyces; lilacinus; ceppo; 251; 216; g/l - nematocida

Európska únia - taliančina - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Taliansko - taliančina - Ministero della Salute

richter pharma ag - lidocaina cloridrato - lidocaina cloridrato - nd, lidocaina cloridrato - 24.65 mg/ml - lidocaine